Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Revvity wird ein jährliches Gewinn- und Umsatzwachstum von 23.9% bzw. 5.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.5% betragen.

Wichtige Informationen

26.2%

Wachstumsrate der Gewinne

26.8%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	6.1%
Zukünftige Eigenkapitalrendite	7.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Is It Time To Consider Buying PerkinElmer, Inc. (NYSE:PKI)?

Dec 12

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

Nov 14

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

Nov 08

PerkinElmer, Inc.'s (NYSE:PKI) Intrinsic Value Is Potentially 48% Above Its Share Price

Oct 28

PerkinElmer declares $0.07 dividend

Oct 27

Gewinn- und Umsatzwachstumsprognosen

NYSE:RVTY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,220	381	896	789	8
12/31/2025	2,996	326	773	720	13
12/31/2024	2,793	240	564	621	13
3/31/2024	2,726	183	97	175	N/A
12/31/2023	2,751	180	10	91	N/A
10/1/2023	2,796	213	-50	34	N/A
7/2/2023	2,837	250	153	227	N/A
4/2/2023	3,024	353	380	460	N/A
1/1/2023	3,312	513	594	680	N/A
10/2/2022	3,599	599	790	876	N/A
7/3/2022	3,748	637	932	1,030	N/A
4/3/2022	3,483	694	1,122	1,220	N/A
1/2/2022	3,828	889	1,325	1,411	N/A
10/3/2021	4,155	1,086	1,478	1,557	N/A
7/4/2021	4,257	1,155	1,380	1,455	N/A
4/4/2021	4,438	1,074	1,234	1,306	N/A
1/3/2021	2,663	631	829	892	N/A
10/4/2020	3,234	412	545	625	N/A
7/5/2020	2,977	294	444	521	N/A
4/5/2020	2,887	226	352	429	N/A
12/29/2019	2,884	228	282	363	N/A
9/29/2019	2,835	235	217	308	N/A
6/30/2019	2,802	251	199	294	N/A
3/31/2019	2,783	247	225	320	N/A
12/30/2018	2,778	237	218	311	N/A
9/30/2018	2,663	128	203	280	N/A
7/1/2018	2,543	149	178	245	N/A
4/1/2018	2,387	147	164	220	N/A
12/31/2017	2,257	157	N/A	288	N/A
10/1/2017	2,182	258	N/A	309	N/A
7/2/2017	2,142	215	N/A	324	N/A
4/2/2017	2,132	210	N/A	372	N/A
1/1/2017	2,116	216	N/A	351	N/A
10/2/2016	1,999	198	N/A	327	N/A
7/3/2016	2,048	199	N/A	314	N/A
4/3/2016	2,076	190	N/A	281	N/A
1/3/2016	2,105	189	N/A	287	N/A
10/4/2015	2,263	176	N/A	258	N/A
6/28/2015	2,241	164	N/A	261	N/A
3/29/2015	2,234	167	N/A	252	N/A
12/28/2014	2,070	130	N/A	282	N/A
9/28/2014	2,221	203	N/A	257	N/A
6/29/2014	2,201	201	N/A	242	N/A
3/30/2014	2,185	176	N/A	215	N/A
12/29/2013	2,158	174	N/A	159	N/A
9/29/2013	2,139	85	N/A	126	N/A
6/30/2013	2,126	73	N/A	99	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RVTYDas prognostizierte Gewinnwachstum (26.2% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: RVTYDie Erträge des Unternehmens (26.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: RVTYEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RVTYDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: RVTYDie Einnahmen des Unternehmens (5.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RVTYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.5%).

Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Price target increased by 8.9% to US$122

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Consensus EPS estimates fall by 15%

Recent updates

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

Consensus EPS estimates increase by 42%, revenue downgraded

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

First quarter 2023 earnings: EPS exceeds analyst expectations

Insider notifies of intention to sell stock

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock